The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 study of osimertinib and bevacizumab as initial treatment for patients with EGFR-mutant lung cancers.
 
Helena Alexandra Yu
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly
Research Funding - Astellas Pharma; AstraZeneca; Clovis Oncology; Incyte; Lilly
 
Sara A. Hayes
No Relationships to Disclose
 
Robert J. Young
No Relationships to Disclose
 
Ai Ni
No Relationships to Disclose
 
Christopher Rodriguez
No Relationships to Disclose
 
Alex Makhnin
No Relationships to Disclose
 
Gregory J. Riely
Consulting or Advisory Role - Genentech; Novartis; Novartis; Roche
Research Funding - ARIAD (Inst); GlaxoSmithKline (Inst); Infinity Pharmaceuticals (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Novartis
 
Mark G. Kris
Consulting or Advisory Role - ARIAD; AstraZeneca; Genentech/Roche
Research Funding - Genentech/Roche (Inst); Puma Biotechnology (Inst)